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for chemotherapy at our institution from July 1, 2002 to February 8, 
2006. 82% of the patients were male, median age at diagnosis was 63 
years, 56% current smokers and 11% never smokers, 81% received 
combined platinum-based chemotherapy. Median follow up time was 
10.5 months. We designed speciﬁc TP53 and MDM2 primers for typing 
both SNPs using the Pyrosequencing® assay. 
Results: Patients genotype frequencies were TP53 Arg/Arg 49%, Arg/
Pro 42%, Pro/Pro 8%, MDM2 T/T 37%, T/G 40%, G/G 17% and were 
in Hardy-Weinberg equilibrium. At multivariable analysis (adjusted for 
gender, smoking status, type of chemotherapy, disease stage, and side 
effects) survival was signiﬁcantly associated with Performance Status 
(PS) [HR 1.54 (1.2-2.0)], histology [SCLC vs. NSCLC - HR 1.51(1.1-
2.1)] and objective response [yes vs. no HR 0.56 (0.4-0.7)] but with 
neither SNP. In contrast, both grade 3-4 toxicity and objective response 
were signiﬁcantly associated with the two SNPs: p53Pro carriers more 
frequently experienced toxicity (HR 1.40, C.I. 1.1-1.8) and objective 
response (HR 1.44, C.I. 1.0-2.0) compared with p53Arg/Arg homozy-
gotes. Conversely, toxicities and objective response were less frequent 
in MDM2309 GG vs. TT homozygotes (HR 0.57, C.I. 0.4-0.9 and 0.61, 
C.I.0.4-0.97 respectively). These ﬁndings are in agreement with the no-
tion that MDM2 GG homozygous cells express higher levels of mdm2, 
thus attenuating the p53 pathway, but not with the alleged greater apop-
totic potential of p53 Arg72. The reliability of the study was strength-
ened by the observation of signiﬁcant associations of toxicity with 
platinum therapy (HR 0.59, C.I. 0.4-0.9), of objective response with 
histology (SCLC vs NSLC HR 2,16, C.I. 1.5-3.1) and of both outcomes 
with PS (toxicity: HR 1.64, C.I. 1.2-2.2; objective response HR 1.57, 
C.I. 1.1-2.2), in agreement with expectations.
Conclusion: This prospective study provides preliminary evidence 
that germ-line p53 and MDM2 SNPs affect toxicity and objective 
response to therapy in lung cancer patients, probably by modulating 
the DNA damage response in the patients’ tissues. In this study the 
assessed genotypes do not affect survival, suggesting that this is mainly 
determined by the tumor aggressiveness and somatic changes acquired 
during carcinogenesis (p53 mutations and MDM2 ampliﬁcation), rather 
than by the constitutional genotype.
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The aberration of cell adhesion is a critical step in the development and 
progression of human non-small cell cancer (NSCLC). The TSLC1/
CADM1 gene on chromosomal region 11q23 was initially identiﬁed as 
a tumor suppressor in NSCLC for its suppressor activity of tumorige-
nicity in nude mice by functional complementation (1). The TSLC1/
CADM1 encodes an immunoglobulin-superfamily cell adhesion mole-
cule that is expressed in the brain, testis, lung and many other epithelial 
tissues. In contrast, the TSLC1/CADM1 gene is inactivated in 30-60% 
of various human cancers, including NSCLC. We have demonstrated 
that TSLC1 protein associates with an actin-binding protein, DAL-1, 
and members of the membrane proteins palmitoylated (MPPs) (2).
In the present study, we report high incidence of promoter methylation 
in the TSLC1/CADM1 and DAL-1/4.1B genes. Using bisulﬁte-sequenc-
ing and bisulﬁte-SSCP analyses, we demonstrated that the promot-
ers of the TSLC1/CADM1 and DAL-1/4.1B genes were methylated 
in 46 (45%) and 59 (57%) of 103 primary NSCLC, respectively. 
Methylations of the TSLC1/CADM1 and DAL-1/4.1B promoters were 
signiﬁcantly associated with a shorter disease-free survival in adeno-
carcinoma patients (p=0.049 and p=0.0011, respectively). However, 
no signiﬁcant correlation was observed between the methylation of the 
TSLC1/CADM1 or DAL-1/4.1B genes and the mutations of the EGFR 
or KRAS2 genes. DAL-1/4.1B methylation was observed preferentially 
in tumors with advanced stages in adenocarcinomas (p=0.0026). On the 
other hand, the TSLC1/CADM1 methylation was signiﬁcantly associ-
ated with heavy smoking history (Brinkman index >800) (P=0.0054). 
Finally, about 70% of primary NSCLC tumors presented epigenetic 
inactivation of either the TSLC1/CADM1 or the DAL-1/4.1B gene, sug-
gesting that aberration of this cascade is deeply involved in progression 
of NSCLC and provide novel prognostic indicators. 
To further investigate the physiological roles of TSLC1/CADM1, we 
generated Tslc1/Cadm1-deﬁcient mice by disrupting exon 1. Tslc1-
/- mice were born normally but Tslc1-/- male mice showed infertility 
due to the disruption of spermatid maturation (3). Notably, 10 of 30 
Tslc1-/- mice (33%) developed lung adenomas at 15 months of age, one 
of which also developed a tumor containing components of adeno-
carcinoma. In lung adenoma, normal bronchiolo-alveolar structure 
disappeared and was completely replaced by the tumor cells with mild 
atypical nuclei showing nest-like arrangement. In lung adenocarci-
noma, tumor cells showed severe atypia and nuclear pleomorphism. 
The average volume of these tumors was 2.7 mm3. In contrast, only 
one of 20 Tslc1+/+ mice developed a small adenoma of 0.0063 mm3 
in volume. Expression proﬁle of the tumors, as well as mutations of the 
Kras2, Tp53, and Egfr, is being investigated. These ﬁndings indicate 
that TSLC1 acts as a tumor suppressor and is deeply involved in lung 
carcinogenesis when its function is abrogated. 
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Background: Lung cancer is the leading cause of cancer death in 
western countries. The overall 5-year survival of non-small cell lung 
carcinomas (NSCLCs) is 10-15%, which improves to ~50% with cura-
tive-intent surgery. The major reason for treatment failure is recurrence 
which occurs in 30-40% of stage I NSCLCs. We hypothesise that 
genomic aberrations may be present in the primary tumour which can 
promote either early tumour recurrence or disease-free survival. Using 
a high-resolution whole-genome array-Comparative Genomic Hybri-
disation (aCGH) platform, we compared genomic aberrations between 
NSCLCs with or without tumour recurrence to identify aberrations that 
correlate with recurrence. Copy-number was then correlated with gene 
expression to identify genes with copy-number driven expression.
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Methods: 98 tissue samples from resected primary squamous cell 
carcinoma (SCC) (n=50) and adenocarcinoma (AC) (n=48) tumours 
were analysed. We compared ACs and SCCs from patients who 
remained disease-free for at least three years (“non-recurrent”) with 
those from patients whose disease recurred within 18 months (“recur-
rent”). Tumour DNA was hybridised against female human genomic 
DNA to a Whole Genome aCGH platform containing ~43,000 probes. 
Copy-number was validated in two genes, GSTM1 and GSTT1, using 
quantitative real-time PCR to determine the reliability of the aCGH 
data. Genomic regions with signiﬁcant copy-number variation (CNV) 
(DNA gain/loss) were identiﬁed with an aberration detection algorithm. 
CNVs were compared between recurrent and non-recurrent tumours 
to identify signiﬁcantly discriminant regions (χ2, p<0.05). To correlate 
copy-number with gene expression, published whole-genome expres-
sion data [Larsen et al (2006) Carcinogenesis; Larsen et al (2007) Clin 
Cancer Res] was correlated with aCGH data. A supervised analysis 
identiﬁed genes signiﬁcantly differentially expressed between recurrent 
and non-recurrent tumours (p<0.05).
Results: Common regions of CNV (>50% of tumours, irrespective of 
recurrence status) frequently observed in ACs and SCCs were gain of 
1q, 3q and 5p and loss of 3p, 6q, 8p and 9p. Putative recurrence-associ-
ated aberrations were deﬁned as regions with frequent CNV (>20%) 
with signiﬁcant differences in the aberration frequency between tumour 
recurrence groups (>15%). In ACs, 15 CNVs discriminated between 
recurrence groups, including gain of 8p11.21-q11.1, 9q34.3, 10p15.3, 
and several regions along 7q and 21q11.2-q21.1 loss (more frequent in 
recurrent tumours) and 4p13-4p12 gain and 14q23.3-q32.33 loss (more 
frequent in non-recurrent ACs). In SCCs, 17 CNVs differed between 
recurrence groups, including 2q22.1-q24.2 and 8q24.3 gain (recur-
rent tumours) and 3p26.3-p24.3 and 8p23.1-8p12 loss (non-recurrent 
tumours) (p<0.05, χ2). Three putative aberrations were identiﬁed in 
both histological subtypes: 8p11.21, 9p21.1-p21.3, and 1p34.1-p33. 
Using gene expression microarray data, genes signiﬁcantly differen-
tially expressed between recurrence groups (p<0.05) were mapped to 
their genomic location. Those located in putative recurrence-associated 
CNVs (15 and 17 in ACs and SCCs, respectively) with high correlation 
between copy-number and expression (r=0.4-0.8) include 7q21.3-
7q32.32 (CYP3A7, CAV2, and WASL), 10p15.3-p11.21 (SVIL, TCF3, 
and RAB18), and 14q23.3-14q32.33 (MARK3, BAG5, SIVA, and 
MTA1).
Conclusions: This study used a whole-genome approach to charac-
terise primary NSCLCs in relation to tumour recurrence. High-resolu-
tion aCGH analysis of NSCLCs identiﬁed focal genomic aberrations 
signiﬁcantly associated with disease recurrence. Integration of gene 
expression data with aCGH data enabled the detection of several genes 
with copy-number driven expression. Genes located in these regions 
may represent novel oncogenes or tumour suppressor genes and are 
currently being validated in an independent set of tumours.
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(FRC0205-23).
C6-05 Cancer Genetics, Wed, 10:30 - 12:15
Genomic and epigenomic instabilities in lung cancer: molecular 
mechanism and clinical implications.
Wang, Yi-Ching 
National Cheng Kung University, Tainan, Taiwan
Genomic study: Genome-wide deletion analysis enables the delinea-
tion of the likely locations of tumor suppressor genes (TSG) and could 
provide molecular markers for disease classiﬁcation. To deﬁne the 
minimal deletion regions (MDRs) in lung cancer, we used 92 microsat-
ellite markers spanning 29 regions in 36 lung squamous cell carcinoma 
(SCC) patients designed to verify the maximal contiguous deletion 
loci. Eight MDRs were found. The candidate genes GAS7 and OVCA2 
in the MDR17pA (17p13.1-p13.2) were further examined for mRNA 
expression. Low expression of the GAS7 gene in 57% of patients ana-
lyzed suggested its importance in lung SCC tumorigenesis. In addition, 
we found a panel of ﬁve microsatellites, which can be used as prog-
nostic biomarkers in lung cancer. Furthermore, alteration in more than 
two genes in the p53 damage response gene and in the double-strand 
break (DSB) repair genes, BRCA1 and XRCC5 was more apparent in 
high chromosome instability patients showing as high fractional allelic 
loss (FAL) than in low FAL patients. Our results provide biomarkers 
that may be used for monitoring tumor progression and for positional 
cloning of new TSGs. Our data show direct evidence that alterations in 
DSB repair and damage response pathways is involved in the genomic 
instability veriﬁed by intensive microsatellites of lung cancer.
Epigenomic study: We established a genome-wide hypermethyl-
ation analysis using the microarray-based strategy called differential 
methylation hybridization (DMH) containing ~8,000 CpG islands to 
identify the regions of hypermethylation in 30 lung cancer patients. The 
genes located in these methylated regions were further identiﬁed by 
the BLAST method. Common methylated genes at the stage-speciﬁc 
manner were identiﬁed. Several genes were speciﬁcally associated 
with adenocarcinoma or squamous lung cancer patients, which are two 
major subtypes of lung cancer. These methylated genes were further 
conﬁrmed for their low mRNA expression in 20 patients. Overexpres-
sion of DNA 5’-cytosine-methyltransferase 1 (DNMT1) has been 
reported in various cancers. However, the mechanism underlying over-
expression of DNMT1 and to the “methylator” phenotype we observed 
